baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Oxford Biomedica PLC/ GB00BDFBVT43 /

2024-04-26 2:31:03 PM	Chg. +9.25	Volume	Bid2:31:32 PM	Ask2:31:32 PM	Market Capitalization	Dividend Y.	P/E Ratio
228.50GBX	+4.22%	6,007 Turnover(GBP): 13,595	228.50Bid Size: 568	230.00Ask Size: 148	182.84 mill.GBP	-	-

GlobeNewswire 04-01 Autolus Therapeutics Announces Changes to its Board of Directors

GlobeNewswire 03-18 Homology Medicines Declares Distribution to Common Stockholders

GlobeNewswire 03-06 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

GlobeNewswire 03-05 Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results

GlobeNewswire 01-29 Oxford Biomedica completes acquisition of ABL Europe

GlobeNewswire 01-23 Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufac...

GlobeNewswire 01-07 Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical ...

GlobeNewswire 01-03 Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

GlobeNewswire 2023-12-07 Business Update

GlobeNewswire 2023-12-04 Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position...

GlobeNewswire 2023-11-16 Q32 Bio and Homology Medicines Announce Merger Agreement

GlobeNewswire 2023-11-14 Homology Medicines Reports Third Quarter 2023 Financial Results

GlobeNewswire 2023-11-09 Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire 2023-09-20 Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed...

GlobeNewswire 2023-09-20 Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023

GlobeNewswire 2023-09-07 Oxford Biomedica to host webinar showcasing the TetraVecta™ system

GlobeNewswire 2022-03-23 Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

GlobeNewswire 2022-03-17 Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Upda...

GlobeNewswire 2022-03-11 Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solution...

GlobeNewswire 2022-03-10 Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Cap...

GlobeNewswire 2022-01-31 Oxford Biomedica announces update to agreement with Sio Gene Therapies

GlobeNewswire 2022-01-31 Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosido...

GlobeNewswire 2022-01-28 Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ establ...

GlobeNewswire 2022-01-17 John Dawson to retire from Oxford Biomedica

Oxford Biomedica PLC/ GB00BDFBVT43 /

If you wish to receive reply to your feedback, please provide your email address.